Researchers at St. Jude Children’s Research Hospital published findings in Science identifying a mechanism by which tumors suppress dendritic cells, the immune system’s antigen-presenting “gatekeepers” that help orchestrate anti-cancer responses. The study links tumor-mediated disruption of mitochondrial function in dendritic cells to downstream immune attenuation, providing a mechanistic explanation for reduced immunotherapy effectiveness in some contexts. For immuno-oncology programs, the work adds a targetable biology angle: rather than only focusing on checkpoint blockade, it highlights how the innate immune network can be functionally disabled upstream of T-cell activation. The publication also reinforces the value of tumor–immune cell cross-talk mapping for identifying combination strategies that restore antigen presentation or mitochondrial competence in dendritic cells.